Biotechnology

BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies

Exclusive Research and Option Agreement With Global Biopharmaceutical Company to Leverage BIORCHESTRA Targeting Technology Platform -BDDS™ - to Develop Nucleic Acid Therapies for Treatment of Neurological Disorders in Multiple Targets CAMBRIDGE, Mass. and DAEJEON, South Korea, March 27, 2023 /PR...

2023-03-27 20:00 1381

ProfoundBio Highlights Broad Antitumor Activity in Preclinical Models and Trial-in-Progress for PRO1184 at AACR 2023 Annual Meeting

WOODINVILLE, Wash. and SUZHOU, China, March 24, 2023 /PRNewswire/ -- ProfoundBio, a clinical stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential, will present two posters from its lead program, PRO1184, a folate receptor alpha (FRα)-...

2023-03-24 20:00 3208

AnPac Bio-Medical Science Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting the Equity Rule on or before July 12, 2023

NEW YORK, March 23, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platf...

2023-03-23 20:00 2837

Ascentage Pharma Announces 2022 Annual Results Including Strong Sales of Olverembatinib and Steady Progress in Transition Towards Biopharma

SUZHOU, China and ROCKVILLE, Md., March 22, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2022. During...

2023-03-23 00:22 2990

CARsgen Announced 2022 Annual Results and Business Updates

SHANGHAI, March 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2022 Annual Results. Business Highlights * Zevor-cel (CT053)...

2023-03-22 20:50 2176

Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023

NEWARK, Del., March 22, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology company, today announced the upcoming presentations of non-clinical data from its oncology pipeline, including BSI-507: anti-PD1ⅹanti-PVRIG bispecific antibody and BSI-508: anti-PD1ⅹanti-CD47 bis...

2023-03-22 20:19 1663

Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer

BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc.,Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Ra...

2023-03-22 12:36 2007

280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting

A broadly acting KRAS Inhibitor, TEB-17231, robustly blocks tumor growth and overcomes KRASG12C inhibitor mediated resistance SHANGHAI, March 21, 2023 /PRNewswire/ -- 280Bio, Inc. a clinical stage biotechnology company, focused on the development of precision oncology medicines, today announced ...

2023-03-21 20:00 1546

Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023

SUZHOU, China, March 21, 2023 /PRNewswire/ -- The 2023 Annual Meeting of American Academy of Dermatology Association (AAD 2023) was held from 17 to21 March 2023 in New Orleans, Louisiana, United States. As one of the largest, most influential and representative of all dermatologic associations, ...

2023-03-21 15:22 1498

Hovione and Ripple Enter Strategic Partnership to Expand Epidel® Platform into Non-Ophthalmic Space

LISBON, Portugal, March 20, 2023 /PRNewswire/ -- Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® plat...

2023-03-20 21:00 1627

Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration

CHENGDU, China, March 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently develop innovative and differentiated pipelines, proactively carry out global strategic collaboration and a...

2023-03-18 08:00 5512

Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' & 'European Heart Journal'

SEOUL, South Korea, March 17, 2023 /PRNewswire/ -- Hanmi Pharmaceuticals (128940.KS), a subsidiary of Hanmi Science (008930.KS) in Korea, announced that the results of large-scale clinical trial with Rosuzet have been published in 'The Lancet' and the 'European Heart Journal'. R&D-oriented pha...

2023-03-17 21:00 3618

Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion

* The company plans to begin construction in the first half of 2023 and commence operations in 2025 * As part of Samsung Biologics' second Bio Campus, Plant 5 will hold a manufacturing capacity of 180,000 liters, expanding the company's total site capacity to 784,000 liters upon its completio...

2023-03-17 19:25 3052

SYMBYX announces promising Sydney Adventist Hospital clinical trial results for Parkinson's using the SYMBYX Neuro - a new light therapy wellness helmet

SYDNEY, March 17, 2023 /PRNewswire/ -- SYMBYX, an Australian medtech company developing light therapies for intractable disease conditions, today announced the results of a Sydney Adventist Hospital (commonly known as the San) triple-blinded, randomised controlled trial investigating the effects ...

2023-03-17 18:30 2085

GCCL Develops PBMC Resource Management System

To enhance accuracy and credibility of sample management and provide real-time information for customers YONGIN, South Korea, March 16, 2023 /PRNewswire/ -- GCCL (Global Clinical Central Lab), a company specializes in clinical trial sample analysis, announced onMar. 17 that it has built a resour...

2023-03-17 09:26 1625

Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration according to Interim Findings from a Phase 2a Study in OA Patients

SEOUL, South Korea, March 16, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed that OLP-1002, a selective inhibitor of Nav1.7 sodium ion channel, showed strong analgesic efficacy and long therapeutic duration according to interim findings from a placebo-co...

2023-03-16 21:00 1847

Akeso Reported 2022 Annual Results

* Strong sales fully demonstrated Akeso's commercialization ability: Products sales totaledRMB1,104.4 million, increasing 422% .开坦尼® (cadonilimab) recorded strong sales ofRMB546.3 million in its first six months of approval in China. 安尼可®(penpulimab injection, PD-1) recorded product sales ofRMB...

2023-03-16 08:26 3425

Bridge Biotherapeutics to Present Updated Preclinical Data of BBT-207 at the AACR 2023 Annual Meeting

* The abstract of BBT-207 preclinical studies is now available on the AACR website * Preclinical data suggests that BBT-207 may have the potential to be used as a broad-spectrum fourth generation EGFR TKI with anti-tumor effects ...

2023-03-15 21:00 2014

HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program

* Applications for physicians trained in Indonesia now open until April 15, 2023 12:00 AM * The Pharmaceutical Industry Fellowship Program provides physicians with the opportunity to experience the various steps of the drug development process ROCKVILLE, Md. and SEOUL, South Korea, March 15, ...

2023-03-15 19:00 1860

Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting

BEIJING and SHANGHAI and BOSTON, Mass., March 14, 2023 /PRNewswire/ -- Jacobin Pharma (1167.HK) today announced that the company will present the results of three preclinical studies of KRASmulti inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 in form of the...

2023-03-15 10:45 3014
1 ... 54555657585960 ... 127